Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib or placebo plus trastuzumab and pertuzumab as maintenance therapy for first-line HER2-positive metastatic breast cancer
CTR20221984Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucatinib in breast cancer, sponsored by Seagen Inc.. Started Nov 2022; status: active.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221984.